Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin?

Research note on the caution around resveratrol or polydatin in Luminal B HER2-positive, ERα-positive breast cancer

Short answer

For HER2-positive, ERα-positive breast cancer, especially Luminal B or triple-positive disease, resveratrol and polydatin should not be treated as casual self-directed adjuncts.

This is not a blanket ban.

It is a real caution based on a specific Δ16HER2 breast-cancer signal.

That signal has not been confirmed in human trials.

The key question is not whether these compounds are always good or always bad.

The key question is how they may behave in a very specific HER2-positive, ER-positive breast-cancer context.

This page gives the short practical answer first.

It then points to the deeper mechanism pages for readers who want the full context.

Why the concern exists

The main caution comes from resveratrol, not from a direct human polydatin trial.

In a Δ16HER2 transgenic breast-cancer mouse model, resveratrol accelerated tumour development instead of suppressing it.

Reported findings included:

earlier tumour onset
more tumours per mouse
stronger proliferative signalling
activation of the mTORC1 / p70S6K / 4EBP1 pathway
marked reduction in ERα expression

This matters because polydatin is metabolised toward resveratrol.

That does not prove polydatin behaves identically in patients.

It does mean the resveratrol signal cannot be ignored in this subtype.

Why Luminal B and HER2+/ERα+ context matter

This caution is strongest in HER2-positive breast cancer with hormone-receptor signalling still in play.

That includes HER2+/ERα+ and many triple-positive settings.

It matters even more when the biology looks Luminal B-like, where HER2 and estrogen signalling can overlap in unstable ways.

The issue is not HER2 positivity alone.

The issue is the combination of:

HER2-driven signalling
ERα-related signalling
the possible presence of Δ16HER2
a compound family linked to resveratrol

What this means for polydatin

Polydatin still has meaningful anticancer findings in breast-cancer research.

It shows apoptosis, CREB suppression, PI3K/Akt and MAPK effects, and stronger signals in TNBC than in HER2-positive disease.

But HER2-positive breast cancer is the one subtype where its conversion toward resveratrol becomes a specific caution, not just a theoretical footnote.

So the practical position is:

do not assume polydatin is safe just because it is not plain resveratrol
do not assume the warning applies to every HER2-positive tumour equally
do not use either as a casual add-on without clinician review

What we can say honestly

What looks real

There is a peer-reviewed Δ16HER2 warning signal in HER2-positive, ER-positive breast cancer
That signal is relevant to resveratrol
Because polydatin converts toward resveratrol, the caution carries over enough to matter clinically

What remains uncertain

We do not know that every HER2-positive tumour expresses clinically meaningful Δ16HER2
We do not know that polydatin has the same net effect as resveratrol in living patients
We do not have human oncology trials proving harm from resveratrol or polydatin in this setting

Practical takeaway

If the question is, "Should a HER2+/ERα+ patient avoid resveratrol or polydatin?", the cleanest answer is:

They should avoid treating them as routine or low-risk supplements.

That is stronger than simple uncertainty.

It is weaker than a proven blanket contraindication.

For HER2-positive, ER-positive, Luminal B-like, or triple-positive disease, this is a discuss first compound pair.

For patients outside that exact context, the warning becomes less certain and more subtype-dependent.

References

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as an oncogenic compound in Δ16HER2 transgenic mice — Andreani, Bartolacci et al., Aging, 2017
https://pmc.ncbi.nlm.nih.gov/articles/PMC5361678/

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers — Cancers, 2019
https://pmc.ncbi.nlm.nih.gov/articles/PMC6678616/

HER2 isoforms co-expression differently tunes mammary tumour phenotypes — Oncotarget, 2017
https://pmc.ncbi.nlm.nih.gov/articles/PMC5589593/

Polydatin down-regulates the phosphorylation level of CREB and induces apoptosis in human breast cancer cells
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0176501

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.